RxDoctor Payments Data

Staci Taylor, APRN

Nurse Practitioner · Pikeville, KYNPI 1457701252

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,998 of the $11,336 with a category attached, or 79.4%. 51 manufacturers reported payments, led by Livanova USA, Inc. at 24.4% of the total. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,336in general payments, 2019–2025

Across 498 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • AbbVie$2K
  • UCB, Inc.$734
  • AstraZeneca$639
  • Biogen$610
  • Lilly USA, LLC$390
  • plus $4K from 45 others

What the payments were for

  • Travel & lodging$2,10819%
  • Food & beverage$8,99879%
  • Education$2302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,336 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$15,559
Medicare patients
218
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant217$313,173
Nurtec OdtRimegepant Sulfate196$198,114
Emgality PenGalcanezumab-Gnlm152$111,821
QuliptaAtogepant87$94,482
Aimovig AutoinjectorErenumab-Aooe96$76,478
Glatiramer Acetate27$59,578
Ajovy AutoinjectorFremanezumab-Vfrm76$53,113
Levetiracetam586$9,418
Lacosamide160$9,158
Pregabalin741$8,503
Primidone393$5,793
Phenobarbital91$3,569
Carbamazepine61$3,076
Divalproex Sodium132$2,998
Carbidopa-LevodopaCarbidopa/Levodopa185$2,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,126$407,656304 claims
PfizerNurtec Odt$158$198,114196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →